- Home
- MCHX vs BCAB Comparison
MCHX vs BCAB Comparison
Compare MCHX & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCHX
- BCAB
- Stock Information
- Founded
- MCHX 2003
- BCAB 2007
- Country
- MCHX United States
- BCAB United States
- Employees
- MCHX N/A
- BCAB N/A
- Industry
- MCHX Business Services
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- MCHX Consumer Discretionary
- BCAB Health Care
- Exchange
- MCHX Nasdaq
- BCAB Nasdaq
- Market Cap
- MCHX 79.9M
- BCAB 77.8M
- IPO Year
- MCHX 2004
- BCAB 2020
- Fundamental
- Price
- MCHX $2.10
- BCAB $1.29
- Analyst Decision
- MCHX
- BCAB Buy
- Analyst Count
- MCHX 0
- BCAB 2
- Target Price
- MCHX N/A
- BCAB $5.00
- AVG Volume (30 Days)
- MCHX 107.8K
- BCAB 645.3K
- Earning Date
- MCHX 10-31-2024
- BCAB 11-07-2024
- Dividend Yield
- MCHX N/A
- BCAB N/A
- EPS Growth
- MCHX N/A
- BCAB N/A
- EPS
- MCHX N/A
- BCAB N/A
- Revenue
- MCHX $48,594,000.00
- BCAB $11,000,000.00
- Revenue This Year
- MCHX N/A
- BCAB N/A
- Revenue Next Year
- MCHX $4.63
- BCAB N/A
- P/E Ratio
- MCHX N/A
- BCAB N/A
- Revenue Growth
- MCHX N/A
- BCAB N/A
- 52 Week Low
- MCHX $1.11
- BCAB $1.14
- 52 Week High
- MCHX $2.40
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- MCHX 63.40
- BCAB 33.19
- Support Level
- MCHX $1.98
- BCAB $1.28
- Resistance Level
- MCHX $2.40
- BCAB $1.72
- Average True Range (ATR)
- MCHX 0.15
- BCAB 0.10
- MACD
- MCHX 0.02
- BCAB -0.02
- Stochastic Oscillator
- MCHX 59.23
- BCAB 4.35
About MCHX Marchex Inc. Class B
Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.